Ovastacin cuts off sperm binding

Because polyspermy disrupts embryonic development, oocytes take several steps to ensure they only fuse with a single sperm. One key step is to prevent additional sperm from binding to the surface of an already-fertilized egg, a blockade that involves the release of secretory granules and cleavage of the glycoprotein ZP2, a component of the zona pellucida matrix that surrounds eggs. ZP2 is cleaved upstream of two acidic amino acids, a cleavage site recognized by the astacin family of metalloendoproteases. Burkart et al. therefore investigated the function of ovastacin, an astacin family member expressed in oocytes.

Ovastacin localized to cortical granules that were exocytosed after fertilization, and recombinant ovastacin cleaved ZP2 when added to zonae pellucidae. Mice lacking ovastacin failed to cleave ZP2 after fertilization, allowing sperm to continue to bind to the surface of early embryos. Ovastacin-null female mice had slightly fewer offspring than wild-type animals but otherwise appeared normal.

The researchers found that ovastacin targeted several sites in ZP2's N terminus. Senior author Jurrien Dean now wants to investigate how this proteolysis blocks sperm binding, a critical question because the molecular interactions between sperm and egg cells remain unknown. He also wants to examine how ovastacin is packaged into oocyte cortical granules and to identify other components of these secretory organelles.